ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

Can NCI Fund 4-Year Grants With 2-Year Stimulus Funds?

March 6, 2009

New Concepts Being Developed By Organ Systems Groups Described

January 2, 1987

In Brief: NCI Gets $937 Million For FY 79 As Congress Adjourns; Cancer Act Renewed For Two Years

October 20, 1978

In Brief: McDonnell Foundation Selects Five For $400,000 Fellowships; Alberts, Verma Picked For Awards

January 4, 1991

Orphan Designation Granted To Advaxis HPV Immunotherapy

May 30, 2014

FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions

January 28, 2011